Prof. Zhiren Zhang 张志仁
Chief Physician, Professor
Department of Cardiology, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of common cardiovascular diseases, including coronary heart disease, hypertension, arrhythmia, heart failure, and cardiomyopathy. Specializes in managing cardiovascular conditions related to cancer therapy.
Dr. Zhang is a Professor, Chief Physician, and Director of Cardiology with a medical doctorate. Dr. Zhang conducted ion channel research in the US for 14 years before returning in 2008. Dr. Zhang's work focuses on CFTR, ENaC, TRP, and calcium-activated chloride channels. Dr. Zhang has published 25 SCI-indexed articles and holds grants from the National Natural Science Foundation.
Professional roles
- Member, American Physiological Society
- Member, American Biophysical Society
- Member, Federation of American Societies for Experimental Biology
- Member, American Heart Association
Name order: in Chinese the family name comes first (Zhang Zhiren). Papers usually list the name as Zhiren Zhang or Zhang Z.
Selected publications
49 papers on PubMed matched by name and affiliation; 20 as first or senior author since 2016. Most recent first- or senior-author papers:
- Circulation, 2026 (senior author): Inhibition of Programmed Cell Death-1 in Cytotoxic CD8(+) T Cells Exacerbates Pressure Overload-Induced Cardiac Injury. PubMed 42677471
- JACC CardioOncol, 2026 (senior author): Cardiovascular Safety of T Cell Engagers: Reassuring Overall, But Not Benign for All. PubMed 42017566
- J Mol Cell Cardiol, 2026 (senior author): Corrigendum to "MFN2-mediated decrease in mitochondria-associated endoplasmic reticulum membranes contributes to sunitinib-induced endothelial dysfunction and hypertension/JMCC 10006". PubMed 41610484
- Cell Metab, 2026 (senior author): Macrophage PD-1 regulates energy expenditure and metabolic dysfunction under immune checkpoint blockade. PubMed 41380676
- J Mol Cell Cardiol, 2025 (senior author): MFN2-mediated decrease in mitochondria-associated endoplasmic reticulum membranes contributes to sunitinib-induced endothelial dysfunction and hypertension. PubMed 39848488
- FASEB J, 2024 (senior author): Blocking CTLA-4 promotes pressure overload-induced heart failure via activating Th17 cells. PubMed 39108204
- Biochim Biophys Acta Mol Basis Dis, 2023 (senior author): Inhibition of YAP by lenvatinib in endothelial cells increases blood pressure through ferroptosis. PubMed 36374802
- Front Pharmacol, 2022 (senior author): Aldosterone-stimulated endothelial epithelial sodium channel (EnNaC) plays a role in cold exposure-induced hypertension in rats. PubMed 36278222
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion